Review
Published on 10 May 2023
Gas6/AXL pathway: immunological landscape and therapeutic potential
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1121130
- 7,102 views
- 5 citations
Type at least 3 characters
1,724 articles
Articles
Original Research
Published on 09 May 2023
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1175617
- 2,973 views
- 3 citations
Original Research
Published on 09 May 2023
Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentity
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1089681
- 2,666 views
- 1 citation
Review
Published on 09 May 2023
The role of fibroblast growth factor 18 in cancers: functions and signaling pathways
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1124520
- 2,516 views
- 5 citations
Original Research
Published on 08 May 2023
A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1142275
- 1,710 views
- 1 citation
Review
Published on 05 May 2023
The emerging roles of Hedgehog signaling in tumor immune microenvironment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1171418
- 3,828 views
- 11 citations
Case Report
Published on 02 May 2023
The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1094770
- 1,968 views
- 4 citations
Original Research
Published on 01 May 2023
A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1159725
- 3,059 views
- 5 citations
Methods
Published on 28 Apr 2023
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1151496
- 2,863 views
Review
Published on 27 Apr 2023
Antibody-based cancer immunotherapy by targeting regulatory T cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1157345
- 7,529 views
- 17 citations
Hypothesis and Theory
Published on 24 Apr 2023
CCNF is a potential pancancer biomarker and immunotherapy target
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1109378
- 3,219 views
- 1 citation
Original Research
Published on 24 Apr 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1115405
- 5,301 views
- 5 citations
Case Report
Published on 21 Apr 2023
Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1156329
- 1,553 views
- 2 citations
Case Report
Published on 20 Apr 2023
Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1169876
- 1,605 views
Original Research
Published on 19 Apr 2023
Zn-Co metal organic frameworks coated with chitosand and Au nanoparticles for chemo-photothermal-targeted combination therapy of liver cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1110909
- 2,024 views
- 5 citations
Original Research
Published on 19 Apr 2023
Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1170942
- 1,807 views